Xenon Pharmaceuticals Inc. (XENE)
Automate Your Wheel Strategy on XENE
With Tiblio's Option Bot, you can configure your own wheel strategy including XENE - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol XENE
- Rev/Share 0.0953
- Book/Share 8.9462
- PB 3.6663
- Debt/Equity 0.0123
- CurrentRatio 64.3548
- ROIC -0.49
- MktCap 2516862080.0
- FreeCF/Share -2.5772
- PFCF -12.411
- PE -10.2644
- Debt/Assets 0.0117
- DivYield 0
- ROE -0.3244
- Rating C+
- Score 2
- Recommendation Sell
- P/E Score 1
- DCF Score 3
- P/B Score 2
- D/E Score 4
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Initiation | XENE | Chardan Capital Markets | -- | Buy | -- | $55 | May 7, 2025 |
| Initiation | XENE | Deutsche Bank | -- | Buy | -- | $67 | Feb. 11, 2025 |
| Resumed | XENE | Raymond James | -- | Outperform | -- | $50 | Oct. 10, 2024 |
| Initiation | XENE | H.C. Wainwright | -- | Buy | -- | $53 | Oct. 1, 2024 |
News
Xenon Pharmaceuticals (XENE) Up 8.7% Since Last Earnings Report: Can It Continue?
Published: June 11, 2025 by: Zacks Investment Research
Sentiment: Positive
Xenon Pharmaceuticals (XENE) reported earnings 30 days ago. What's next for the stock?
Read More
Polarean's Xenon MRI technology to feature in over 30 studies at American Thoracic Society events
Published: May 15, 2025 by: Proactive Investors
Sentiment: Positive
Polarean Imaging PLC (AIM:POLX, OTC:PLLWF), the AIM-listed medical imaging company, will have its Xenon-based magnetic resonance imaging (MRI) technology showcased in more than 30 clinical studies at the American Thoracic Society's annual meetings in San Francisco this month. The company, which develops imaging platforms designed to assess lung function, has been selected as a featured participant at the ATS Respiratory Innovation Summit, taking place on 16–17 May.
Read More
Xenon Q1 Loss Narrower Than Expected, Pipeline Development in Focus
Published: May 13, 2025 by: Zacks Investment Research
Sentiment: Positive
XENE incurs narrower-than-estimated first-quarter 2025 loss. Studies on lead candidate, azetukalner, in epilepsy and MDD are progressing well.
Read More
Wall Street Analysts See a 48.15% Upside in Xenon Pharmaceuticals (XENE): Can the Stock Really Move This High?
Published: May 05, 2025 by: Zacks Investment Research
Sentiment: Positive
The average of price targets set by Wall Street analysts indicates a potential upside of 48.2% in Xenon Pharmaceuticals (XENE). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Read More
Xenon to Showcase Long-Term 36-Month Azetukalner Data at AAN 2025
Published: April 04, 2025 by: GlobeNewsWire
Sentiment: Neutral
VANCOUVER, British Columbia and BOSTON, April 04, 2025 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-focused biopharmaceutical company dedicated to discovering, developing, and delivering life-changing therapeutics for patients in need, today announced multiple presentations at the upcoming American Academy of Neurology Annual Meeting (AAN 2025), taking place April 5-9, 2025 in San Diego, CA. Three posters will be presented, including long-term data from the ongoing X-TOLE open-label extension (OLE) study of azetukalner in patients with focal onset seizures (FOS). The Company will also present an exploratory efficacy analysis of FOS seizure subtypes from the X-TOLE study, as well …
Read More
Xenon Pharmaceuticals Inc. (XENE) Q4 2024 Earnings Call Transcript
Published: February 27, 2025 by: Seeking Alpha
Sentiment: Neutral
Xenon Pharmaceuticals Inc. (NASDAQ:XENE ) Q4 2024 Earnings Conference Call February 27, 2025 4:30 PM ET Company Participants Chad Fugere - Vice President, Investor Relations Ian Mortimer - President and Chief Executive Officer Chris Kenney - Chief Medical Officer Sherry Aulin - Chief Financial Officer Conference Call Participants Paul Matteis - Stifel Caroline Poacher - JPMorgan Brian Skorney - Baird Jason Gerberry - Bank of America Sarah Schram - William Blair Laura Chico - Wedbush Securities Joseph Thome - TD Cowen Douglas Tsao - H.C. Wainwright Operator Hello and thank you for standing by.
Read More
Xenon Reports Fourth Quarter & Full Year 2024 Financial Results and Business Update
Published: February 27, 2025 by: GlobeNewsWire
Sentiment: Neutral
– Phase 3 topline data from azetukalner FOS epilepsy program planned for H2 2025 in support of NDA filing and potential commercial launch
Read More
Xenon to Present at the 45th Annual TD Cowen Healthcare Conference
Published: February 25, 2025 by: GlobeNewsWire
Sentiment: Neutral
VANCOUVER, British Columbia and BOSTON, Feb. 25, 2025 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-focused biopharmaceutical company dedicated to discovering, developing, and delivering life-changing therapeutics for patients in need, today announced that the company will present at the 45th Annual TD Cowen Healthcare Conference taking place in Boston, MA from March 3-5, 2025.
Read More
Xenon to Report Q4 and Full Year 2024 Financial Results on February 27, 2025
Published: February 20, 2025 by: GlobeNewsWire
Sentiment: Neutral
VANCOUVER, British Columbia and BOSTON, Feb. 20, 2025 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-focused biopharmaceutical company dedicated to discovering, developing, and delivering life-changing therapeutics for patients in need, today announced it will report its fourth quarter 2024 financial results after the close of U.S. financial markets on Thursday, February 27, 2025.
Read More
About Xenon Pharmaceuticals Inc. (XENE)
- IPO Date 2014-11-05
- Website https://www.xenon-pharma.com
- Industry Biotechnology
- CEO Mr. Ian C. Mortimer C.M.A., CPA, M.B.A.
- Employees 316